Biosyent (RX) investor relations material

Business model and operating principles

• Focuses on specialty pharmaceuticals and oral health products, with the latter acquired in March 2024.

• Operates a capital-light, cash-generating model, emphasizing late-stage or on-market products to reduce risk.

• Products are globally sourced, either acquired or in-licensed, and distributed in Canada and select international markets.

• Prioritizes brand differentiation and invests in growing unique brands.

• R&D is limited to development and commercialization, not discovery.

Financial performance and capital allocation

• Achieved a 24% compound annual growth rate over 15 years, with 63 consecutive profitable quarters since 2010.

• Reduced share count by 23% over eight years and consistently pays dividends, with high insider ownership at 27%.

• 2023 revenue was CAD 43 million, EBITDA over CAD 12 million, and net income after tax CAD 9 million.

• Share buybacks have positively impacted EPS and return on equity, with a 900 basis point ROE improvement.

• Generated CAD 9 million in operating cash last year, deploying CAD 2.5 million to buybacks.

Recent acquisition and integration

• Acquired Oral Science, a Montreal-based oral health company, for CAD 25.5 million in March 2024.

• Oral Science contributed CAD 3 million in revenue and CAD 500,000 in EBITDA in its first month post-acquisition.

• Oral Science's business is one-third owned assets and two-thirds in-licensed, mirroring the pharma model.

• Leadership from Oral Science remains, aiming to double the business in five to six years.

• Acquisition was immediately accretive and is expected to significantly boost consolidated revenue and EBITDA.